Dalfampridine Improves Sensorimotor Function in Rats With Chronic Deficits After Middle Cerebral Artery Occlusion [Basic Sciences]
Conclusions—
Dalfampridine improves sensorimotor function in the rat permanent middle cerebral artery occlusion model. Dalfampridine extended-release tablets (prolonged release fampridine outside the United States) are used to improve walking in patients with multiple sclerosis, and these preclinical data provide a strong rationale for examining the potential of dalfampridine to treat chronic stable deficits in stroke patients.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT01605825
Source: Stroke - Category: Neurology Authors: Iaci, J. F., Parry, T. J., Huang, Z., Finklestein, S. P., Ren, J., Barrile, D. K., Davenport, M. D., Wu, R., Blight, A. R., Caggiano, A. O. Tags: Animal models of human disease, Other Stroke Treatment - Medical Basic Sciences Source Type: research
More News: Brain | Clinical Trials | Multiple Sclerosis | Neurology | Physical Therapy | Stroke | Study